ACAT2 and nonpapillary renal cell carcinoma: This study identified LPE18:1 as a PAT-derived metabolite that promotes ccRCC progression via CAPZA1-mediated stabilization of SIRT6, which facilitates ACAT2 expression to reprogram lipid metabolism.